These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38380162)

  • 21. Identification and determination of selected angiotensin II receptor antagonist group drugs by HPLC method.
    Czerwińska K; Mazurek AP
    Acta Pol Pharm; 2011; 68(6):831-7. PubMed ID: 22125946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1-7)-Mas axes in pressure overload-induced cardiac remodeling in male mice.
    Wang X; Ye Y; Gong H; Wu J; Yuan J; Wang S; Yin P; Ding Z; Kang L; Jiang Q; Zhang W; Li Y; Ge J; Zou Y
    J Mol Cell Cardiol; 2016 Aug; 97():180-90. PubMed ID: 27210827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of pharmacokinetic bioequivalence between generic and branded amoxicillin formulations. A post-marketing clinical study on healthy volunteers.
    Del Tacca M; Pasqualetti G; Di Paolo A; Virdis A; Massimetti G; Gori G; Versari D; Taddei S; Blandizzi C
    Br J Clin Pharmacol; 2009 Jul; 68(1):34-42. PubMed ID: 19660001
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is the newest angiotensin-receptor blocker azilsartan medoxomil more efficacious in lowering blood pressure than the older ones? A systematic review and network meta-analysis.
    Wang JG; Zhang M; Feng YQ; Ma CS; Wang TD; Zhu ZM; Kario K
    J Clin Hypertens (Greenwich); 2021 May; 23(5):901-914. PubMed ID: 33609077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thymol-Based Hydrophobic Deep Eutectic Solvents as a Green Approach for Screening Polar Nitrosamines in Sartans Pharmaceutical Products by Ultrasound-Assisted Dispersive Liquid-Liquid Microextraction Combined with HPLC-DAD.
    Novotny TS; Monteiro MA; de Lima PC; Ochs SM; Maranho RLDN; Vaz FAS; Marques FFC
    J Pharm Sci; 2023 May; 112(5):1231-1245. PubMed ID: 36481416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of myocardial infarction, heart failure, and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan in patients.
    Yoo YG; Lim MJ; Kim JS; Jeong HE; Ko H; Shin JY
    Medicine (Baltimore); 2023 Nov; 102(46):e36098. PubMed ID: 37986329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evergreened drugs or evergreened profits?
    Siddalingaiah S; Fugh-Berman A
    J Eval Clin Pract; 2022 Dec; 28(6):1119-1126. PubMed ID: 35543377
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada: A Population-Based Time Series Analysis.
    Leclerc J; Blais C; Rochette L; Hamel D; Guénette L; Poirier P
    Circ Cardiovasc Qual Outcomes; 2017 Oct; 10(10):. PubMed ID: 28974512
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Pathak P; Dawane J
    J Clin Diagn Res; 2016 Sep; 10(9):FC07-FC09. PubMed ID: 27790457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Olmesartan medoxomil: a review of its use in the management of hypertension.
    Scott LJ; McCormack PL
    Drugs; 2008; 68(9):1239-72. PubMed ID: 18547134
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.
    Nishida Y; Takahashi Y; Susa N; Kanou N; Nakayama T; Asai S
    Cardiovasc Diabetol; 2013 Nov; 12():159. PubMed ID: 24180232
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic evaluation of four angiotensin II receptor blockers in the treatment of hypertension.
    Miller LA; Wade R; Dai D; Cziraky MJ; Ramaswamy K; Panjabi S
    Curr Med Res Opin; 2010 Jun; 26(6):1307-20. PubMed ID: 20370377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials.
    Stumpe KO
    Clin Ther; 2004; 26 Suppl A():A33-7. PubMed ID: 15291378
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improving Adherence to Treatment and Reducing Economic Costs of Hypertension: The Role of Olmesartan-Based Treatment.
    Costa FV
    High Blood Press Cardiovasc Prev; 2017 Sep; 24(3):265-274. PubMed ID: 28695464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Angiotensin II type 1 receptor blockers decrease kynurenic acid production in rat kidney in vitro.
    Zakrocka I; Targowska-Duda KM; Wnorowski A; Kocki T; Jóźwiak K; Turski WA
    Naunyn Schmiedebergs Arch Pharmacol; 2019 Feb; 392(2):209-217. PubMed ID: 30370429
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generic versus branded medicines: An observational study among patients with chronic diseases attending a public hospital outpatient department.
    Das M; Choudhury S; Maity S; Hazra A; Pradhan T; Pal A; Roy RK
    J Nat Sci Biol Med; 2017; 8(1):26-31. PubMed ID: 28250671
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estimation of Potential Savings Through Therapeutic Substitution.
    Johansen ME; Richardson C
    JAMA Intern Med; 2016 Jun; 176(6):769-75. PubMed ID: 27159226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers: a meta-analysis.
    Wang L; Zhao JW; Liu B; Shi D; Zou Z; Shi XY
    Am J Cardiovasc Drugs; 2012 Oct; 12(5):335-44. PubMed ID: 22920046
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bioavailability and pharmacokinetic comparison between generic and branded azithromycin capsule: a randomized, double-blind, 2-way crossover in healthy male Thai volunteers.
    Boonleang J; Panrat K; Tantana C; Krittathanmakul S; Jintapakorn W
    Clin Ther; 2007 Apr; 29(4):703-10. PubMed ID: 17617293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and bioequivalence study of three oral formulations of valsartan 160 mg: a single-dose, randomized, open-label, three-period crossover comparison in healthy Indian male volunteers.
    Iqbal M; Khuroo A; Batolar LS; Tandon M; Monif T; Sharma PL
    Clin Ther; 2010 Mar; 32(3):588-96. PubMed ID: 20399995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.